Loading stock…

Max Healthcare Institute Limited (543220) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Max Healthcare Institute Limited

543220Market cap $9.13BPrice $9.4

Country🇮🇳India

SectorHealthcare

IndustryHealthcare Services

Runs a network of premium hospitals across North India, treating everything from cardiac emergencies to organ transplants. One of the country's fastest-growing healthcare chains, it's expanding beds faster than rivals can build new wings.

In Bastion Portfolios?

52W Return-31%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+17%9

Revenue Forecast

Rev CAGR (1y)+38%9

Rev CAGR (3y)+26%9

Rev CAGR (5y)+16%9

Earnings Forecast

EPS Growth Y+1+23%8

EPS Growth Y+2+25%8

EPS Growth Y+3+22%8

Quality

Margins

EBIT Margin21%8

Net Income Margin17%7

Free Cash Flow Margin2%3

Debt

Net Debt/EBITDA1.25

Efficiency

ROE14%6

ROAna–

Earnings Stability77

GEAR+STRONG71

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)441

P/E Ratio (Forward 3y)321

P/BV8.22

EV Multiples

EV/EBITDA Fwd291

EV/EBIT Fwd372

Yield

Free Cash Flow Yield0.2%3

Dividend Yield0.2%1

Momentum

Short term

1 month return-9%3

3 month return-20%2

YTD return-14%3

Mid term

Price vs 52wHigh74%4

1 year return-20%2

Long term

3 year return+61%6

5 year return+158%8

Risk Shield

Price Risk

Beta0.29

Volatility26%8

Free Cash Flow

Free Cash Flow Margin2%3

Free Cash Flow Yield0.2%3

Quality

ROCE25%9

Earnings Stability77

Net Debt/EBITDA1.25

02Growth

Is it actually growing, and how fast?

543220Max Healthcare Institute

Revenue FY26$897M

GROWTH RATING↗

VERY STRONG92 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+17%9

Revenue, next 1Y+38%9

Revenue, next 3Y, CAGR+26%9

Revenue, next 5Y, CAGR+16%9

EARNINGS FORECAST▾SCORE

EPS growth, FY27E+23%8

EPS growth, FY28E+25%8

EPS growth, FY29E+22%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 92% of companies worldwide.

Revenue grew 17%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

Revenue is set to grow 26%/yr over the next 3 years, ahead of most of the market.9/10

Revenue grew 17%/yr over the last 3 years and is set to grow 26%/yr from here.

The runway holds up: revenue is set to grow 16%/yr over five years.9/10

Earnings are set to grow in step with sales (EPS about 23%/yr vs revenue 26%/yr).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Hyper Compounder

A top-tier grower that's speeding up.

03Price Momentum

Is the market behind it right now?

543220Max Healthcare Institute

Total return Current235%

Price return Current233%

MOMENTUM RATING↗

WEAK26 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-9%3

3-month return-20%2

YTD return-14%3

MID & LONG-TERM▾SCORE

% of 52-week high74%4

1-year return-20%2

3-year return+61%6

5-year return+158%8

MOMENTUM ASSESSMENT

STRENGTHS

Strong long-term results. Long-term holders have seen +61% over three years and +158% over five, ahead of 60% of the market.

WATCH

None flagged.

WEAKNESSES

It's down 20% over the past year, now 26% below its 52-week high. That is lagging the market.

The stock is underperforming over the past month (-9%), over three months (-20%) and so far this year (-14%).

BOTTOM LINE

Outperformer in a Drawdown

A proven multi-year compounder now in a meaningful pullback well below its 52-week high. This is the classic fork: either a buy-the-dip in an intact uptrend, or the early stage of a trend change. Wait for the short-term slide to stabilise before adding. The one thing to watch: the one-year trend is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Max Healthcare. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

543220Max Healthcare Institute

Revenue FY26$897M

GROWTH RATING↗

VERY STRONG92 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+17%9

Revenue, next 1Y+38%9

Revenue, next 3Y, CAGR+26%9

Revenue, next 5Y, CAGR+16%9

EARNINGS FORECAST▾SCORE

EPS growth, FY27E+23%8

EPS growth, FY28E+25%8

EPS growth, FY29E+22%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 92% of companies worldwide.

Revenue grew 17%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

Revenue is set to grow 26%/yr over the next 3 years, ahead of most of the market.9/10

Revenue grew 17%/yr over the last 3 years and is set to grow 26%/yr from here.

The runway holds up: revenue is set to grow 16%/yr over five years.9/10

Earnings are set to grow in step with sales (EPS about 23%/yr vs revenue 26%/yr).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Hyper Compounder

A top-tier grower that's speeding up.

03Price Momentum

Is the market behind it right now?

543220Max Healthcare Institute

Total return Current235%

Price return Current233%

MOMENTUM RATING↗

WEAK26 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-9%3

3-month return-20%2

YTD return-14%3

MID & LONG-TERM▾SCORE

% of 52-week high74%4

1-year return-20%2

3-year return+61%6

5-year return+158%8

MOMENTUM ASSESSMENT

STRENGTHS

Strong long-term results. Long-term holders have seen +61% over three years and +158% over five, ahead of 60% of the market.

WATCH

None flagged.

WEAKNESSES

It's down 20% over the past year, now 26% below its 52-week high. That is lagging the market.

The stock is underperforming over the past month (-9%), over three months (-20%) and so far this year (-14%).

BOTTOM LINE

Outperformer in a Drawdown

04Value

Are you paying a fair price for it?

Stop guessing on Max Healthcare. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community